secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001171843-21-005671
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst CBO Megan Sniecinski departs Aug 9; severance of $658,634 plus accelerated option vesting
--------------------------------------------------------------------------------

- Megan Sniecinski, Chief Business Officer, separates effective August 9, 2021; previously disclosed on Aug 3.
- Severance payment of $658,634.04 paid in equal installments over one year.
- 100% of unvested options from July 2019 & Dec 2019, and 75% from Dec 2020, accelerate to vested.
- COBRA premiums paid for up to 18 months; 180-day post-separation option exercise window.
- Agreement includes one-year non-compete in therapeutic areas (HAE, FOP, PNH, etc.) and non-solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184321005671/0001171843-21-005671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184321005671/f8k_080921.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer